Yoshito Komatsu
Hokkaido University
338 Papers
1.1K Citations
Yoshito Komatsu is an academic researcher from Hokkaido University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 36, co-authored 278 publications.
Chat about Author
Papers
CA125 kinetics as a potential biomarker for ascites progression during taxane plus ramucirumab therapy in patients with advanced gastric cancer.
Akira Ueda,Satoshi Yuki,Takayuki Ando,Iori Motoo,K. Ito,Yosuke Kito,Miho Sakumura,Yuko Ueda,Shinya Kajiura,Naokatsu Nakada,K. Nakajima,Ayumu Hosokawa,Kazuaki Harada,T. Kawamoto,Yoshito Komatsu,Ichiro Yasuda +15 more
TL;DR: In this paper , the authors investigated the association between serum CA125 and therapeutic efficacy for advanced gastric cancer (AGC) patients treated with taxane plus ramucirumab (TAX/RAM).
Systematic review and individual patient data based meta-analysis of palonosetron trials for chemotherapy induced nausea and vomiting.
Yuki Okada,Koji Oba,Naoto Furukawa,Yoshito Komatsu,Yoshimasa Kosaka,Kenji Okita,Satoshi Yuki,Luigi Celio,Matti Aapro +8 more
TL;DR: A systematic review of clinical trials for any randomized controlled trials reporting CINV outcomes for a single 1-day-dexamethasone (D1 group) containing antiemetic regimen in chemotherapy-naive adult patients scheduled to receive a MEC or AC-containing chemotherapy found complete response in the 5-day study period.
The impacts of initiating regorafenib with reduced dose on treatment outcomes in metastatic colorectal cancer.
Takeshi Kawakami,Kazuaki Harada,Takatsugu Ogata,Qingjiang Hu,Kunihiro Fushiki,Kotoe Oshima,Shigenori Kadowaki,Hiroya Taniguchi,Kei Muro,Ryota Nakanishi,Koji Ando,Sho Nambara,Takashi Yamamura,T. Kawamoto,Yoshito Komatsu,Eiji Oki,Toshiki Masuishi,Kentaro Yamazaki,Satoshi Yuki +18 more
TL;DR: In this paper , the impact of starting regorafenib (REG) at a reduced dose on treatment outcomes in the real-world setting has not been fully investigated, however, the authors suggest that starting REG at reduced dose may contribute to reducing the frequency and delaying the onset of HFSR, whereas it may not affect efficacy.
TP53 gain of function mutation as a prognostic factor in high-methylated metastatic colorectal cancer: Translational research of TRICOLORE study.
Kota Ouchi,Shonosuke Wakayama,Shin Takahashi,Yasuhide Yamada,Yoshito Komatsu,Ken Shimada,Tatsuro Yamaguchi,Hidekazu Shirota,Masanobu Takahashi,Chikashi Ishioka +9 more
TL;DR: In this paper , the authors analyzed the association among primary tumor site (PS), genome-wide DNA methylation status (GWMS), and TP53 mutation subtypes about prognosis in metastatic colorectal cancer (mCRC).
Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1
Yoshito Komatsu,Yutaka Takahashi,Yutaka Kimura,Hisashi Oda,Yusuke Tajima,Shigeyuki Tamura,Joji Sakurai,Shigeru Tatebe,Masahiro Takahashi,Yuh Sakata,Masaki Kitajima,T. Sakamoto,Shigetoyo Saji +12 more
TL;DR: In this paper , the authors compared tailored irinotecan plus s-1 therapy with S-1 monotherapy for the treatment of patients with advanced/recurrent gastric cancer.